Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02898727 : A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Age 18 years or older

- Metastatic HER2 positive breast cancer

- 1-5 synchronous brain metastases

- At least one metastases requiring treatment

- Maximum volume of any single PTV <10cm3

- Summated volume of all lesions to be treated with SRS is < 15cm3. If a lesion is too
small for treatment and will be observed, then its volume is not included in this

- ECOG 0-2

- Absent or stable extracranial disease or active extracranial disease that is likely to
be controlled with further HER-2 targeted therapy

- Receiving systemic HER2 targeted therapy, or planned to receive within 4 weeks of
completion of brain metastasis treatment

- Able to undergo MRI scanning

Exclusion Criteria:

- Previous treatment to the target brain metastases (excluding surgery within 6 weeks of

- Previous whole brain radiotherapy (WBRT)

- Any brain metastasis that is greater than 30mm in size and unable to be resected

- Leptomeningeal disease

- Pregnant or breastfeeding
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557